Immix Biopharma, Inc.
IMMX
Jodie situation report
Immix Biopharma, Inc.'s move is being confirmed by its market group.
No new filing conclusion is available. 23 of 24 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 2 directly disclosed connections are confirming.
- At least 16 of 24 members remain active in the next snapshot.
- Capital-flow agreement rises above 55%.
- A filing-linked outsider such as XNCR begins moving with the group.
Invalidation: The live read weakens if participation falls to 8 of 24 members or fewer.
Who this business touches
The relationships behind IMMX
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
KYTXKyverna Therapeutics, Inc.competitorMar 25, 2026 ▾
“In addition, we face competition from companies developing cell therapies for immune-mediated disease, some of which include Kyverna Therapeutics, Inc.; Cabaletta Bio, Inc.; Fate Therapeutics Inc.; and Arcellx, Inc.”
PRTAProthena Corporation plccompetitorMar 25, 2026 ▾
“Specifically, we face competition from companies developing therapies for AL amyloidosis which include Prothena Corp, Caelum Biosciences (n/k/a Alexion/AstraZeneca), and Janssen/Johnson & Johnson.”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 4 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
IMMX is currently a Participant in the organic co-movement group Rare Disease Biotech. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 2 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.